Evidence map›Paper›PMID 26413425›Full record

ArticleJAK-STAT2015

The oncogenic FIP1L1-PDGFRα fusion protein displays skewed signaling properties compared to its wild-type PDGFRα counterpart.

Serge Haan, Christelle Bahlawane, Jiali Wang, Petr V Nazarov, Arnaud Muller, René Eulenfeld, Claude Haan, Catherine Rolvering, Laurent Vallar, Venkata P Satagopam and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in JAK-STAT, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 3 countries.

Serge HaanMolecular Disease Mechanisms Group; Life Sciences Research Unit; University of Luxembourg; Luxembourg , Luxembourg.
Christelle BahlawaneMolecular Disease Mechanisms Group; Life Sciences Research Unit; University of Luxembourg; Luxembourg , Luxembourg.
Jiali WangMolecular Disease Mechanisms Group; Life Sciences Research Unit; University of Luxembourg; Luxembourg , Luxembourg.
Petr V NazarovGenomics Research Unit; Luxembourg Institute of Health; Luxembourg , Luxembourg.
Arnaud MullerGenomics Research Unit; Luxembourg Institute of Health; Luxembourg , Luxembourg.
René EulenfeldSignal Transduction Group; Life Sciences Research Unit; University of Luxembourg; Luxembourg , Luxembourg.
Claude HaanSignal Transduction Group; Life Sciences Research Unit; University of Luxembourg; Luxembourg , Luxembourg.
Catherine RolveringSignal Transduction Group; Life Sciences Research Unit; University of Luxembourg; Luxembourg , Luxembourg.
Laurent VallarGenomics Research Unit; Luxembourg Institute of Health; Luxembourg , Luxembourg.
Venkata P SatagopamLuxembourg Center for Systems Biomedicine; University of Luxembourg ; Esch-sur-Alzette, Luxembourg.
Thomas SauterSystems Biology Group; Life Sciences Research Unit; University of Luxembourg; Luxembourg , Luxembourg.
Monique Yvonne WiesingerSystems Biology Group; Life Sciences Research Unit; University of Luxembourg; Luxembourg , Luxembourg.
University of Luxembourg · LULuxembourg Institute of Health · LU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant activation of oncogenic kinases is frequently observed in human cancers, but the underlying mechanism and resulting effects on global signaling are incompletely understood. Here, we demonstrate that the oncogenic FIP1L1-PDGFRα kinase exhibits a significantly different signaling pattern compared to its PDGFRα wild type counterpart. Interestingly, the activation of primarily membrane-based signal transduction processes (such as PI3-kinase- and MAP-kinase- pathways) is remarkably shifted toward a prominent activation of STAT factors. This diverging signaling pattern compared to classical PDGF-receptor signaling is partially coupled to the aberrant cytoplasmic localization of the oncogene, since membrane targeting of FIP1L1-PDGFRα restores activation of MAPK- and PI3K-pathways. In stark contrast to the classical cytokine-induced STAT activation process, STAT activation by FIP1L1-PDGFRα does neither require Janus kinase activity nor Src kinase activity. Furthermore, we investigated the mechanism of STAT5 activation via FIP1L1-PDGFRα in more detail and found that STAT5 activation does not involve an SH2-domain-mediated binding mechanism. We thus demonstrate that STAT5 activation occurs via a non-canonical activation mechanism in which STAT5 may be subject to a direct phosphorylation by FIP1L1-PDGFRα.

Indexed as

AKTFIP1L1-PDGFRαJanus kinaseMAP kinasePlatelet-derived growth factorSH2-domainSrc kinaseSTAT-factor

Identifiers

PMID26413425
PMCPMC4583054
OpenAlexW1883602769

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.